1237 ET - Jazz Pharmaceuticals' move to buy Chimerix could be the start of deal-making by the biopharma, analysts at Piper Sandler say. Piper's David Amsellem and Alex von Riesemann say the $935 million deal is a sensible and targeted use of capital that doesn't get in the way of Jazz's ability to execute on additional M&A and doesn't entail Jazz taking on development risk. Piper notes that Jazz management has previously touted capacity for a multi-billion-dollar transaction or series of deals, and the analysts say they would like to see Jazz turn its attention to bolstering its epilepsy franchise. Jazz up 2% to $141.67. (colin.kellaher@wsj.com)
(END) Dow Jones Newswires
March 05, 2025 12:37 ET (17:37 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.